HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

10.310

-0.070-0.67%

Volume:4.54M

Turnover:46.60M

Market Cap:4.20B

PE:-11.63

High:10.440

Open:10.440

Low:10.120

Close:10.380

52wk High:679.500

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.52

T/O Rate:1.46%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.887

ROE:-62.88%

ROA:-32.06%

PB:8.64

PE(LYR):-11.63

PS:- -

Loading ...

Overview Company News Filings

Transthera Sciences (Nanjing) Inc - Co and Shanghai Allist Announce Collaboration for Nsclc Clinical Trial

THOMSON REUTERS

TransThera Sciences signs pact with Allist Pharma to study TT-00973 plus firmonertinib in EGFR-mutant NSCLC

TransThera Sets 18 June 2026 Online EGM to Approve New H Share Award Scheme and Service Provider Sublimit

Bulletin Express

TransThera Sciences Launches 2026 H-Share Award Scheme, Capping New Share Issuance at 10% of Outstanding Stock

Bulletin Express

TRANSTHERA-B Shares Drop Over 3% Following Third Fundraising via Discounted Placement This Year

Stock Track | TransThera-B Soars 6.12% Intraday Following Share Placement for Oncology Drug Development

TransThera Sciences Seeks HK$156 Million via Share Offering

MT Newswires Live

Stock Track | TRANSTHERA-B Plummets 5.22% in Pre-Market After Announcing Private Placement at 18% Discount

TransThera Sciences places 3.84 million new H-shares at HK$40.83, raising up to HK$156.62 million

Bulletin Express

TRANSTHERA-B Announces Private Placement of Shares at a Discount to Raise Capital

TransThera Sciences prices 3,836,000-share placement at HK$40.83 each

Transthera Sciences (Nanjing) Inc - to Place 3,836,000 New H Shares at HK$40.83 per Share

THOMSON REUTERS

Transthera Sciences (Nanjing) Inc - Gross Proceeds Expected at HK$156.62 Mln, Net Proceeds at HK$152.13 Mln

THOMSON REUTERS

TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial

MT Newswires Live

TRANSTHERA-B's Core Product Demonstrates Efficacy in Advanced Solid Tumors in Nature Communications Publication

TransThera Highlights Promising Phase Ib/II Results for Tinengotinib in Nature Communications

Bulletin Express

Stock Track | TRANSTHERA-B Plummets 5.70% Intraday on Clinical Data Release and Sector Weakness

TransThera Sciences Issues 5.09 Million H Shares in April Placement, Expanding Total Share Capital to 404.08 Million

Bulletin Express

TRANSTHERA-B's Third Fundraising in Under a Year: 18% Discounted Placement Raises HK$290 Million While Prior Funds Remain Unused

TransThera聚焦创新药研发，2025年净亏损约2.96亿元，核心管线获监管突破

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/02617/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":10.31,"timestamp":1787299687057,"preClose":10.38,"halted":0,"volume":4543800,"delay":0,"changeRate":-0.006743737957610817,"floatShares":312000000,"shares":407000000,"eps":-0.8868345239122081,"marketStatus":"Not Yet Opened","change":-0.07,"latestTime":"08-21 16:08:07","open":10.44,"high":10.44,"low":10.12,"amount":46601191,"amplitude":0.030829,"askPrice":10.31,"askSize":5000,"bidPrice":10.3,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":-0.8863140920731754,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":10.38,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.5223118835745755,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-32.06%","roe":"-62.88%","lyrEps":-0.886835,"volumeRatio":0.5223118835745755,"shares":407000000,"dividePrice":0,"high":10.44,"amplitude":0.030829,"preClose":10.38,"low":10.12,"week52Low":9.01,"pbRate":"8.64","week52High":679.5,"institutionHeld":0,"latestPrice":10.31,"committee":0.354839,"eps":-0.8868345239122081,"divideRate":0,"volume":4543800,"delay":0,"ttmEps":-0.8863140920731754,"open":10.44,"prevYearClose":114.9,"prevWeekClose":10.33,"prevMonthClose":9.95,"prevQuarterClose":11.55,"fiveDayClose":10.33,"twentyDayClose":10.19,"sixtyDayClose":38.7,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-08-21","current":-11.632445,"percent":0.95122,"low":-380.446233,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"high":-10.87103,"avg":-114.757849,"sd":96.187407,"marketCap":4205641106},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106}],"updateTime":1787481598284},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638251086","title":"Transthera Sciences (Nanjing) Inc - Co and Shanghai Allist Announce Collaboration for Nsclc Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638251086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638251086?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:28","pubTimestamp":1779802135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nFWN4230IV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638351080","title":"TransThera Sciences signs pact with Allist Pharma to study TT-00973 plus firmonertinib in EGFR-mutant NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2638351080","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638351080?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:28","pubTimestamp":1779802134,"startTime":"0","endTime":"0","summary":"TransThera entered a clinical trial collaboration and supply agreement with Allist to test TT-00973-MS with firmonertinib in EGFR-mutant NSCLC.Parties will run a multi-center, open-label Phase II study in locally advanced or metastatic patients to assess safety, efficacy of the combination.TransThera will sponsor the trial, covering operations and costs; Allist will supply firmonertinib mesylate tablets at no charge.Results will guide talks on a potential Phase III trial for the combination regimen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 26, 2026, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL1VvBRZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161999293","title":"TransThera Sets 18 June 2026 Online EGM to Approve New H Share Award Scheme and Service Provider Sublimit","url":"https://stock-news.laohu8.com/highlight/detail?id=1161999293","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161999293?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:23","pubTimestamp":1779463424,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. will convene an extraordinary general meeting (EGM) on 18 June 2026 at 9:00 a.m. via the Vistra eVoting Portal. Shareholders will vote by poll on one special and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176623290","title":"TransThera Sciences Launches 2026 H-Share Award Scheme, Capping New Share Issuance at 10% of Outstanding Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1176623290","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176623290?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:23","pubTimestamp":1779463394,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (abbrev. “TransThera Sciences”) has received shareholder approval for a new 10-year H-Share Award Scheme aimed at enhancing staff motivation, strengthening...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145272584","title":"TRANSTHERA-B Shares Drop Over 3% Following Third Fundraising via Discounted Placement This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1145272584","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145272584?lang=en_us&edition=fundamental","pubTime":"2026-05-19 11:24","pubTimestamp":1779161061,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) experienced significant volatility in its share price this morning. The stock initially plunged over 9% to an intraday low of HKD 45.24 before staging a strong rebound to HKD...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VXUS","BK1161","02617","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188373033","title":"Stock Track | TransThera-B Soars 6.12% Intraday Following Share Placement for Oncology Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1188373033","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188373033?lang=en_us&edition=fundamental","pubTime":"2026-05-19 10:49","pubTimestamp":1779158940,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B's stock soared 6.12% during intraday trading on Tuesday, following the company's announcement of a capital raise to fund the expansion of its key drug pipeline.TransThera Sciences...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885855","title":"TransThera Sciences Seeks HK$156 Million via Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885855","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636885855?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:38","pubTimestamp":1779154686,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) (HKG:2617) said it was looking to raise HK$156.6 million via a share offering, according to a Tuesday filing with the Hong Kong bourse.The drugmaker is seeking investors ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185523900","title":"Stock Track | TRANSTHERA-B Plummets 5.22% in Pre-Market After Announcing Private Placement at 18% Discount","url":"https://stock-news.laohu8.com/highlight/detail?id=1185523900","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185523900?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:37","pubTimestamp":1779154637,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B's stock plummeted 5.22% in pre-market trading on Tuesday, following the company's announcement of a private placement of shares at a significant discount to the previous closing...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110856569","title":"TransThera Sciences places 3.84 million new H-shares at HK$40.83, raising up to HK$156.62 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1110856569","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110856569?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:43","pubTimestamp":1779144200,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. disclosed a best-effort placement of 3.84 million new H-shares at HK$40.83 each, representing an 18.01 % discount to the 18 May 2026 closing price of HK$49.80 and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115520139","title":"TRANSTHERA-B Announces Private Placement of Shares at a Discount to Raise Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1115520139","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115520139?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:40","pubTimestamp":1779144031,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced that on May 19, 2026, prior to the trading session, the company entered into a placement agreement with a placement agent. Under this agreement, the placement...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636800401","title":"TransThera Sciences prices 3,836,000-share placement at HK$40.83 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2636800401","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636800401?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:31","pubTimestamp":1779143470,"startTime":"0","endTime":"0","summary":"Transthera Sciences  launched a best-efforts private placement of 3,836,000 new H shares at HK$ 40.83 each, targeting at least six professional or institutional investors.Gross proceeds expected at about HK$ 156.62 million; net proceeds estimated at about HK$ 152.13 million.The placement price implies an 18.01% discount to the May 18 close of HK$ 49.8.Proceeds earmarked mainly for development of new indications for tinengotinib, with the balance for working capital and general corporate purposes.Shares are expected to be issued on May 27, subject to listing approval, with the new stock representing about 0.95% of existing issued shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original cont","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL2D9Vh3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636040990","title":"Transthera Sciences (Nanjing) Inc - to Place 3,836,000 New H Shares at HK$40.83 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2636040990","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636040990?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:30","pubTimestamp":1779143448,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V1H7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636004091","title":"Transthera Sciences (Nanjing) Inc - Gross Proceeds Expected at HK$156.62 Mln, Net Proceeds at HK$152.13 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2636004091","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636004091?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:30","pubTimestamp":1779143448,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V1H7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636049845","title":"TransThera Sciences' Tinengotinib Shows Anti-tumor Efficacy in Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636049845","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636049845?lang=en_us&edition=fundamental","pubTime":"2026-05-18 12:12","pubTimestamp":1779077575,"startTime":"0","endTime":"0","summary":"TransThera Sciences   said its anti-tumor drug candidate, tinengotinib, was found to offer benefit to patients in a clinical trial conducted in China, according to a Sunday filing with the Hong Kong bourse.Results published in the Nature Communications journal showed that tinengotinib demonstrated anti-tumor activity both as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors and advanced biliary tract cancer.Subjects who received tinengotinib as a monotherapy achieved an objective response rate of 16.7%, while those in the combination arm had an ORR of 22.6%, the firm said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153908883","title":"TRANSTHERA-B's Core Product Demonstrates Efficacy in Advanced Solid Tumors in Nature Communications Publication","url":"https://stock-news.laohu8.com/highlight/detail?id=1153908883","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153908883?lang=en_us&edition=fundamental","pubTime":"2026-05-17 18:48","pubTimestamp":1779014915,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced the publication of exploratory clinical results for its core product, tienegotinib, both as a monotherapy and in combination with atezolizumab for treating advanced...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183414332","title":"TransThera Highlights Promising Phase Ib/II Results for Tinengotinib in Nature Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=1183414332","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183414332?lang=en_us&edition=fundamental","pubTime":"2026-05-17 18:42","pubTimestamp":1779014561,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) reported new Phase Ib/II data showing that its spectrum-selective multi-kinase inhibitor tinengotinib delivered notable antitumor activity both as a standalone therapy...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151965178","title":"Stock Track | TRANSTHERA-B Plummets 5.70% Intraday on Clinical Data Release and Sector Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=1151965178","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151965178?lang=en_us&edition=fundamental","pubTime":"2026-05-13 11:41","pubTimestamp":1778643704,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B's stock fell sharply by 5.70% during intraday trading on Wednesday.The decline followed the release of clinical data for the company's core product tiengoitinib, presented at the 2026...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141413135","title":"TransThera Sciences Issues 5.09 Million H Shares in April Placement, Expanding Total Share Capital to 404.08 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1141413135","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141413135?lang=en_us&edition=fundamental","pubTime":"2026-05-06 16:03","pubTimestamp":1778054607,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. filed its Monthly Return for the period ended 30 April 2026, highlighting a placement-driven expansion of its equity base. The company allotted 5.09 million new H...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162258215","title":"TRANSTHERA-B's Third Fundraising in Under a Year: 18% Discounted Placement Raises HK$290 Million While Prior Funds Remain Unused","url":"https://stock-news.laohu8.com/highlight/detail?id=1162258215","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162258215?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:12","pubTimestamp":1777543925,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617.HK), a Hong Kong-listed pre-revenue biotech company, announced a new share placement after market close on April 14, 2026. The company plans to issue 5.085 million new H shares at...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190223337","title":"TransThera聚焦创新药研发，2025年净亏损约2.96亿元，核心管线获监管突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1190223337","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190223337?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:49","pubTimestamp":1776955792,"startTime":"0","endTime":"0","summary":"根据TransThera Sciences (Nanjing), Inc.（以下简称“公司”）披露的2025年度报告，报告期内公司继续专注于肿瘤及炎症等领域的小分子药物研发，尚未实现收入，全年净亏损由上一年度的人民币2.7461亿元扩大至人民币2.9596亿元（同比增长约7.8%）。公司董事会及管理层在年内继续强化内部治理结构，研发投入占主要成本比例，核心产品在临床与注册方面取得重要突破。...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"TransThera聚焦创新药研发，2025年净亏损约2.96亿元，核心管线获监管突破","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":140,"code":"91000000","status":"200"}]}}